Viracta Therapeutics (STU:RYIS) Common Stock : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics Common Stock?

Viracta Therapeutics's quarterly common stock stayed the same from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) and stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

Viracta Therapeutics's annual common stock stayed the same from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) and stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Viracta Therapeutics Common Stock Historical Data

The historical data trend for Viracta Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viracta Therapeutics Common Stock Chart

Viracta Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

Viracta Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial												-	-	-	-	-

Viracta Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Viracta Therapeutics (STU:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (STU:RYIS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

VIRX:USA

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Viracta Therapeutics (STU:RYIS) Headlines

No Headlines